S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
What's in Democrats' big bill? Climate, health care, savings
Dems push Biden climate, health priorities toward Senate OK
Shift in war's front seen as grain leaves Ukraine; plant hit
NASDAQ:AMRN

Amarin - AMRN Stock Forecast, Price & News

$1.29
+0.01 (+0.78%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.23
$1.30
50-Day Range
$1.27
$1.99
52-Week Range
$1.11
$5.97
Volume
2.75 million shs
Average Volume
2.98 million shs
Market Capitalization
$512.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Amarin MarketRank™ Forecast

Analyst Rating
Hold
1.83 Rating Score
Upside/​Downside
93.8% Upside
$2.50 Price Target
Short Interest
Bearish
6.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.11mentions of Amarin in the last 14 days
Based on 18 Articles This Week
Insider Trading
Acquiring Shares
$92,950 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.26) to ($0.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

816th out of 1,283 stocks

Pharmaceutical Preparations Industry

396th out of 615 stocks

AMRN stock logo

About Amarin (NASDAQ:AMRN) Stock

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on AMRN shares. Northland Securities downgraded shares of Amarin from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 4th. SVB Leerink downgraded shares of Amarin from an "outperform" rating to a "market perform" rating and cut their target price for the company from $10.00 to $3.00 in a research note on Thursday, May 5th. HC Wainwright cut Amarin from a "buy" rating to a "neutral" rating and lowered their price target for the company from $10.00 to $3.00 in a report on Thursday, May 5th. StockNews.com upgraded Amarin from a "sell" rating to a "hold" rating in a report on Wednesday, July 27th. Finally, JPMorgan Chase & Co. cut Amarin from a "neutral" rating to an "underweight" rating in a report on Friday, May 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $2.50.

Amarin Stock Performance

Shares of NASDAQ:AMRN traded up $0.01 during trading on Friday, reaching $1.29. 2,753,320 shares of the stock were exchanged, compared to its average volume of 2,977,770. Amarin has a 12-month low of $1.11 and a 12-month high of $5.97. The firm has a market cap of $512.14 million, a price-to-earnings ratio of -5.16 and a beta of 1.85. The firm's 50-day moving average price is $1.55 and its 200 day moving average price is $2.42.

Amarin (NASDAQ:AMRN - Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). The company had revenue of $94.44 million during the quarter, compared to analysts' expectations of $88.21 million. Amarin had a negative return on equity of 13.63% and a negative net margin of 21.05%. The firm's revenue was down 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.02 EPS. As a group, equities research analysts forecast that Amarin will post -0.26 EPS for the current year.

Insiders Place Their Bets

In related news, Director Olsen Per Wold purchased 55,000 shares of the firm's stock in a transaction on Monday, June 13th. The stock was purchased at an average price of $1.69 per share, for a total transaction of $92,950.00. Following the acquisition, the director now directly owns 149,000 shares in the company, valued at $251,810. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.90% of the stock is owned by company insiders.

Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Stock News Headlines

Does Amarin Deserve a Spot in Your Portfolio after Earnings ?
Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio.
Form S-8 AMARIN CORP PLC\UK - StreetInsider.com
Amarin Corp: Q2 Earnings Insights - Benzinga
Amarin (NASDAQ:AMRN) Stock Rating Upgraded by StockNews.com
Amarin (NASDAQ:AMRN) Upgraded at StockNews.com
See More Headlines
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

AMRN Company Calendar

Last Earnings
8/03/2022
Today
8/07/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMRN
Fax
N/A
Employees
560
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+93.8%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$7.73 million
Pretax Margin
-18.89%

Debt

Sales & Book Value

Annual Sales
$583.19 million
Cash Flow
$0.06 per share
Book Value
$1.46 per share

Miscellaneous

Free Float
393,435,000
Market Cap
$512.14 million
Optionable
Optionable
Beta
1.85

Social Links


Key Executives

  • Mr. Karim Mikhail (Age 51)
    Pres, CEO & Director
    Comp: $1.19M
  • Dr. Steven B. Ketchum Ph.D. (Age 57)
    Pres of R&D, Exec. VP and Chief Scientific Officer
    Comp: $827.62k
  • Mr. Jason M. Marks J.D. (Age 46)
    Exec. VP, Chief Legal and Compliance Officer & Corp. Sec.
    Comp: $626.07k
  • Mr. Joseph T. Kennedy J.D. (Age 54)
    Exec. VP of Strategic Initiatives & Gen. Counsel
    Comp: $980.18k
  • Mr. Aaron D. Berg (Age 59)
    Exec. VP & Pres of U.S.
    Comp: $745.52k
  • Mr. Thomas Charles Reilly (Age 50)
    CFO & Sr. VP
  • Dr. David Keenan
    Sr. VP of Technical Operations
  • Ms. Lisa M. DeFrancesco (Age 42)
    Sr. VP of Corp. Affairs & Investor Relations
  • Alina Kolomeyer
    Director of Communications
  • Mr. Jordan Zwick (Age 35)
    Sr. VP of Corp. Bus. Devel.













AMRN Stock - Frequently Asked Questions

Should I buy or sell Amarin stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amarin stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View analyst ratings for Amarin
or view top-rated stocks.

What is Amarin's stock price forecast for 2022?

6 Wall Street research analysts have issued 1-year target prices for Amarin's shares. Their AMRN stock forecasts range from $1.50 to $3.00. On average, they predict Amarin's share price to reach $2.50 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

How has Amarin's stock performed in 2022?

Amarin's stock was trading at $3.37 at the beginning of the year. Since then, AMRN shares have decreased by 61.7% and is now trading at $1.29.
View the best growth stocks for 2022 here
.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our earnings forecast for Amarin
.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its quarterly earnings data on Wednesday, August, 3rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.05. The biopharmaceutical company had revenue of $94.44 million for the quarter, compared to the consensus estimate of $88.21 million. Amarin had a negative net margin of 21.05% and a negative trailing twelve-month return on equity of 13.63%. The company's quarterly revenue was down 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.02 earnings per share.

What is John Thero's approval rating as Amarin's CEO?

43 employees have rated Amarin CEO John Thero on Glassdoor.com. John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include SCP Investment LP (0.69%), Van ECK Associates Corp (0.26%), Cutter & CO Brokerage Inc. (0.21%), Private Advisor Group LLC (0.12%), Regis Management CO LLC (0.09%) and Avantax Advisory Services Inc. (0.06%). Company insiders that own Amarin stock include David M Stack, John F Thero, Joseph S Zakrzewski, Lars Ekman, Michael Wayne Kalb, Olsen Per Wold and Steven B Ketchum.
View institutional ownership trends for Amarin
.

How do I buy shares of Amarin?

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $1.29.

How much money does Amarin make?

Amarin (NASDAQ:AMRN) has a market capitalization of $512.14 million and generates $583.19 million in revenue each year. The biopharmaceutical company earns $7.73 million in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does Amarin have?

Amarin employs 560 workers across the globe.

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.
Read More

When was Amarin founded?

Amarin was founded in 1991.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for Amarin is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.

This page (NASDAQ:AMRN) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.